通过对进行协调来掩盖酸的生物活性:朝着生物还原性抗癌剂
David M Goodman1, Cornelia U Ritter1, Erin Chen1
1School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
研究人员开发了新的 (III) 复合物,以掩盖强效抗癌药物沃里诺斯塔特 (SAHA). 这些复合物旨在针对低氧瘤的向释放,减少对健康组织的毒性.
科学领域:
- 药用化学 医学化学
- 药物输送系统 药物输送系统
- 癌症治疗方法 癌症治疗方法
背景情况:
- 强效的抗癌药物如沃里诺斯塔特 (SAHA) 具有非选择性毒性,限制了它们的临床应用.
- 基斯脱乙酶抑制剂 (SAHA) 显示出高细胞毒性,但缺乏癌细胞和健康细胞之间的区别.
研究的目的:
- 开发基于的新型预制药,以掩盖SAHA的活性,以提高瘤选择性.
- 为了使SAHA能够针对性地传递到低氧瘤微环境中.
主要方法:
- 合成和表征 (III) 复合物的合成和表征,其稳定由环和环四等宏环.
- 实验室生物测试以评估SAHA的抗癌活性和掩盖.
- 循环电压测量和化学还原实验以确认前药物激活机制.
主要成果:
- (III) 复合物在体外表现出较低的抗癌活性,这表明SAHA的有效掩盖.
- 观察到复合物的长期稳定性.
- 实验支持了SAHA释放通过减少瘤中的Co (III) 中心的假设.
结论:
- (III) 复合物显示出作为新型抗癌剂的潜力,通过掩盖药物细胞毒性以进行向输送.
- 需要进一步开发以改善这些前药物的细胞吸收.
更多相关视频
08:40Synthesis of Metal Nanoparticles Supported on Carbon Nanotube with Doped Co and N Atoms and its Catalytic Applications in Hydrogen Production
Published on: December 6, 2021
09:00An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
Published on: March 18, 2015
相关概念视频
Structural Isomerism
Isomers are different chemical species that have the same chemical formula. Structural isomerism of coordination compounds can be divided into two subcategories, the linkage isomers and coordination-sphere isomers.
Linkage isomers occur when the coordination compound contains a ligand that can bind to the transition metal center through two different atoms. For example, the CN− ligand can bind through the carbon atom or through the nitrogen atom. Similarly, SCN− can...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Coordination Compounds and Nomenclature
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
